Pear Therapeutics

A Company of "Firsts"

Pear is a place for pioneers: for those with a passion for investigating unchartered territories and boldly advancing medicine and patient treatments.

We are leading the development of a new segment in the healthcare industry, prescription digital therapeutics, or PDTs.

In September 2017, Pear became the first company to receive FDA authorization for a prescription digital therapeutic, or PDT, to treat disease with the market authorization of reSET® for the treatment of Substance Use Disorder. Our second product, reSET-O® for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation by FDA and was authorized in December 2018. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program and was authorized in March 2020. Pear is one of nine companies taking part in the FDA’s Digital Health Software Precertification Pilot Program.  Other companies participating include Apple, Fitbit, Johnson & Johnson, and Roche.

Our team is a reflection of the novel nature of our work. Physicians, clinicians, and researchers work side-by-side with software engineers, product designers, and developers to create software as medicine. While our backgrounds may be diverse, we’re united by a mission to help patients and pioneer a new way of treating serious disease.

Our teams in Boston, Raleigh and San Francisco are growing rapidly. To explore open positions, please visit here.